Cargando…
The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults
Bacterial central nervous system (CNS) infections are serious and carry significant morbidity and mortality. They encompass many syndromes, the most common being meningitis, which may occur spontaneously or as a consequence of neurosurgical procedures. Many classes of antimicrobials are in clinical...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774927/ https://www.ncbi.nlm.nih.gov/pubmed/36551500 http://dx.doi.org/10.3390/antibiotics11121843 |
_version_ | 1784855518969331712 |
---|---|
author | Haddad, Nicholas Carr, Maddie Balian, Steve Lannin, James Kim, Yuri Toth, Courtney Jarvis, Jennifer |
author_facet | Haddad, Nicholas Carr, Maddie Balian, Steve Lannin, James Kim, Yuri Toth, Courtney Jarvis, Jennifer |
author_sort | Haddad, Nicholas |
collection | PubMed |
description | Bacterial central nervous system (CNS) infections are serious and carry significant morbidity and mortality. They encompass many syndromes, the most common being meningitis, which may occur spontaneously or as a consequence of neurosurgical procedures. Many classes of antimicrobials are in clinical use for therapy of CNS infections, some with established roles and indications, others with experimental reporting based on case studies or small series. This review delves into the specifics of the commonly utilized antibacterial agents, updating their therapeutic use in CNS infections from the pharmacokinetic and pharmacodynamic perspectives, with a focus on the optimization of dosing and route of administration that have been described to achieve good clinical outcomes. We also provide a concise synopsis regarding the most focused, clinically relevant information as pertains to each class and subclass of antimicrobial therapeutics. CNS infection morbidity and mortality remain high, and aggressive management is critical in ensuring favorable patient outcomes while averting toxicity and upholding patient safety. |
format | Online Article Text |
id | pubmed-9774927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97749272022-12-23 The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults Haddad, Nicholas Carr, Maddie Balian, Steve Lannin, James Kim, Yuri Toth, Courtney Jarvis, Jennifer Antibiotics (Basel) Review Bacterial central nervous system (CNS) infections are serious and carry significant morbidity and mortality. They encompass many syndromes, the most common being meningitis, which may occur spontaneously or as a consequence of neurosurgical procedures. Many classes of antimicrobials are in clinical use for therapy of CNS infections, some with established roles and indications, others with experimental reporting based on case studies or small series. This review delves into the specifics of the commonly utilized antibacterial agents, updating their therapeutic use in CNS infections from the pharmacokinetic and pharmacodynamic perspectives, with a focus on the optimization of dosing and route of administration that have been described to achieve good clinical outcomes. We also provide a concise synopsis regarding the most focused, clinically relevant information as pertains to each class and subclass of antimicrobial therapeutics. CNS infection morbidity and mortality remain high, and aggressive management is critical in ensuring favorable patient outcomes while averting toxicity and upholding patient safety. MDPI 2022-12-19 /pmc/articles/PMC9774927/ /pubmed/36551500 http://dx.doi.org/10.3390/antibiotics11121843 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Haddad, Nicholas Carr, Maddie Balian, Steve Lannin, James Kim, Yuri Toth, Courtney Jarvis, Jennifer The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults |
title | The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults |
title_full | The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults |
title_fullStr | The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults |
title_full_unstemmed | The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults |
title_short | The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults |
title_sort | blood–brain barrier and pharmacokinetic/pharmacodynamic optimization of antibiotics for the treatment of central nervous system infections in adults |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774927/ https://www.ncbi.nlm.nih.gov/pubmed/36551500 http://dx.doi.org/10.3390/antibiotics11121843 |
work_keys_str_mv | AT haddadnicholas thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT carrmaddie thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT baliansteve thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT lanninjames thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT kimyuri thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT tothcourtney thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT jarvisjennifer thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT haddadnicholas bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT carrmaddie bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT baliansteve bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT lanninjames bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT kimyuri bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT tothcourtney bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults AT jarvisjennifer bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults |